From Seekingalpha · SA Transcripts · · 30s
Kymera Therapeutics Q3 2026 Earnings Call
Kymera Therapeutics CEO discusses Phase I trial results for KT-579.
In brief
Kymera Therapeutics CEO discusses Phase I trial results for KT-579. Kymera Therapeutics reported Q3 2026 earnings with Phase I trial results for KT-579. Originally reported by Seekingalpha.
Q3 2026 Earnings Call
Kymera Therapeutics held Q3 2026 earnings call on October 29, 2026.
Company Participants
Justine Koenigsberg, Nello Mainolfi, Terence Rooney, and Bruce Jacobs joined the call.
KT-579 Phase I Results
The call discussed KT-579 Phase I healthy volunteer trial results.
The headline
Kymera Therapeutics reported Q3 2026 earnings with Phase I trial results for KT-579.
